Want to see INBP full AI Analyst Report?
Total Valuation
Integrated BioPharma has a market cap or net worth of $5.28M. The enterprise value is $4.19M.
Market Cap$5.28M
Enterprise Value$4.19M
Share Statistics
Integrated BioPharma has 31,059,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,059,610
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Integrated BioPharma’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -13.04%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-13.04%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee327.40K
Profits Per Employee-21.21K
Employee Count134
Asset Turnover1.73
Inventory Turnover4.71
Valuation Ratios
The current PE Ratio of Integrated BioPharma is ―. Integrated BioPharma’s PEG ratio is 0.00444.
PE Ratio―
PS Ratio0.13
PB Ratio0.32
Price to FCF6.25
Price to Operating Cash Flow4.51
PEG Ratio0.00444
Income Statement
In the last 12 months, Integrated BioPharma had revenue of 43.87M and earned -2.84M in profits. Earnings per share was -0.09.
Revenue43.87M
Gross Profit800.00K
Operating Income-2.71M
Pretax Income-2.56M
Net Income-2.84M
EBITDA-1.32M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was 1.24M and capital expenditures -346.00K, giving a free cash flow of 895.00K billion.
Operating Cash Flow1.24M
Free Cash Flow895.00K
Free Cash Flow per Share0.03
Dividends & Yields
Integrated BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.07
52-Week Price Change-45.16%
50-Day Moving Average0.18
200-Day Moving Average0.23
Relative Strength Index (RSI)43.89
Average Volume (3m)14.44K
Important Dates
Integrated BioPharma upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateSep 25, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Integrated BioPharma as a current ratio of 3.00, with Debt / Equity ratio of 17.42%
Current Ratio3.00
Quick Ratio1.42
Debt to Market Cap0.22
Net Debt to EBITDA1.06
Interest Coverage Ratio-225.42
Taxes
In the past 12 months, Integrated BioPharma has paid 279.00K in taxes.
Income Tax279.00K
Effective Tax Rate-0.11
Enterprise Valuation
Integrated BioPharma EV to EBITDA ratio is -3.19, with an EV/FCF ratio of 4.69.
EV to Sales0.10
EV to EBITDA-3.19
EV to Free Cash Flow4.69
EV to Operating Cash Flow3.38
Balance Sheet
Integrated BioPharma has $4.47M in cash and marketable securities with $3.08M in debt, giving a net cash position of $1.39M billion.
Cash & Marketable Securities$4.47M
Total Debt$3.08M
Net Cash$1.39M
Net Cash Per Share$0.04
Tangible Book Value Per Share$0.57
Margins
Gross margin is 1.82%, with operating margin of -6.17%, and net profit margin of -6.48%.
Gross Margin1.82%
Operating Margin-6.17%
Pretax Margin-5.84%
Net Profit Margin-6.48%
EBITDA Margin-3.00%
EBIT Margin-6.17%
Analyst Forecast
The average price target for Integrated BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-19.28%
EPS Growth Forecast-441.42%